

March 31, 2023



Camber Pharmaceuticals issues voluntary nationwide recall of atovaquone oral suspension, USP 750 mg/5 mL due to potential *Bacillus cereus* contamination in the product

At Prime Therapeutics Management, we want to help you receive the best possible care. Visit **[PrimeTherapeutics.com/DrugRecalls](https://www.PrimeTherapeutics.com/DrugRecalls)** to review the latest FDA drug recalls.

Camber Pharmaceuticals has posted a lot recall of atovaquone oral suspension.

About this recall:

Camber Pharmaceuticals is voluntarily recalling lot number E220182 of atovaquone oral suspension, USP 750 mg/5 mL to the consumer/user level, due to the potential of *Bacillus cereus* contamination in the product.

Atovaquone oral suspension, USP is indicated for prevention and treatment of *Pneumocystis jiroveci* pneumonia (PCP) in adults and children 13 years of age and older who cannot tolerate other medicines, such as trimethoprim-sulfamethoxazole. The product is packaged in 210 mL HDPE bottle in a mono carton.

What this means to you:

In the population most at risk, the immunocompromised population, there is a reasonable probability that microbial contamination of atovaquone oral suspension can result in disseminated, life-threatening infections such as inflammation of the heart and soft tissue infections causing death of the tissue. To date, Camber has not received any reports of adverse events related to this recall.

Camber Pharmaceuticals, Inc. is notifying its distributors and customers by our Reverse Logistics Company, Inmar, by mailings and emails and is arranging for returns of all recalled atovaquone oral suspension, USP.

Consumers/distributors/retailers that carry product that is being recalled should stop using/return to place of purchase/discard/contact their doctor, etc.

Consumers with questions regarding this recall can contact Inmar by phone at **877.597.0878**, Monday–Friday, 9 a.m.–5 p.m. Eastern Time (ET) or email **RxRecalls@Inmar.com**. Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking or using this drug product.